{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:30:27Z","timestamp":1786480227441,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Accurate renal dosing of high dose melphalan as conditioning chemotherapy is critical for patients with multiple myeloma undergoing autologous stem cell transplant (ASCT). In clinical practice, serum creatinine (sCr) is used to eGFR for dosing calculations. The objective of our study was to compare sCr based eGFR to serum cystatin C based eGFR for melphalan dosing in patients undergoing ASCT for multiple myeloma to determine discrepancies in dosing and the effect on patient centered outcomes including chemotherapy-related toxicity, hospitalization and to assess IMWG response criteria at 3 and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective study including 76 patients with multiple myeloma who received melphalan conditioning before ASCT. Melphalan dosing in all patients was based on pre-transplant eGFR calculated from sCr (200 mg\/m2 for eGFR &gt;50 mL\/min, 140 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for eGFR &lt; 50 mL\/min). We calculated eGFR using both sCr and cystatin C levels prior to transplantation and observed the 30-day hospitalization from symptoms of melphalan toxicity. We identified a discordant patient group, whose cystatin C eGFR was calculated less than 50 mL\/min compared to sCr eGFR &gt;50 mL\/min and would have qualified for a reduced melphalan dose.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 76 patients, 13 (17%) were identified as having received a higher than intended dose of melphalan when eGFR was estimated using sCr rather than cystatin C (200 mg\/m2 rather than 140 mg\/m2, \u201cdiscordant dosing\u201d). 100% of discordant patients were hospitalized within 30 days of melphalan dosing compared to 60% of the concordant patients whose eGFR was greater than 50 mL\/min with both cystatin C and sCr based eGFR, with melphalan dosing 200 mg\/m2 (p = 0.006). Furthermore, patients with discordant dosing had a significantly longer hospitalization duration of 7days compared to 2.5 days in patients with concordant dosing (p=0.0014). More patients qualified for dose reduction using cystatin C based eGFR compared to combined sCr-cystatin C based eGFR (p=0.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Discordance between creatinine- and cystatin C-based eGFR calculations in ASCT patients was linked to inconsistent melphalan dosing and associated with an increase in adverse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000001107","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:00:40Z","timestamp":1772211640000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective Analysis"],"prefix":"10.34067","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5491-8226","authenticated-orcid":false,"given":"Benjamin","family":"Teruel","sequence":"first","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, SC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-2142","authenticated-orcid":false,"given":"Ashley L.","family":"Golbus","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, SC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9268-8096","authenticated-orcid":false,"given":"Elaine","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, SC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Myeloma & Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8516-1839","authenticated-orcid":false,"given":"Patrick T.","family":"Murray","sequence":"additional","affiliation":[{"name":"University College Dublin School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James","family":"Davis","sequence":"additional","affiliation":[{"name":"School of Medicine, Department of Clinical Pharmacy and Outcome Sciences, Medical University of South Carolina, Charleston, SC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-2787","authenticated-orcid":false,"given":"Blaithin A.","family":"McMahon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"6","key":"B1-20260430","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol."},{"key":"B2-20260430","doi-asserted-by":"crossref","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"9","key":"B3-20260430","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jtct.2022.06.013","article-title":"High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma","volume":"28","author":"Ali","year":"2022","journal-title":"Transplant Cell Ther."},{"issue":"3","key":"B4-20260430","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"B5-20260430","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jtct.2022.02.014","article-title":"A review of propylene glycol-free melphalan conditioning for hematopoietic cell transplantation for multiple myeloma and light chain amyloidosis","volume":"28","author":"Hari","year":"2022","journal-title":"Transplant Cell Ther."},{"issue":"5","key":"B6-20260430","doi-asserted-by":"crossref","first-page":"201","DOI":"10.14740\/jh1148","article-title":"The impact of renal impairment in multiple myeloma patients undergoing autologous stem cell transplantation with melphalan conditioning","volume":"12","author":"Ursu","year":"2023","journal-title":"J Hematol."},{"issue":"33","key":"B7-20260430","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol."},{"issue":"10","key":"B8-20260430","doi-asserted-by":"crossref","first-page":"e15059","DOI":"10.1111\/ctr.15059","article-title":"Impact of weight and creatinine adjustments on the accuracy of Cockcroft-gault equation in hematopoietic cell transplant patients","volume":"37","author":"Emanuel","year":"2023","journal-title":"Clin Transplant."},{"issue":"11","key":"B9-20260430","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/jch.13696","article-title":"Addressing the problem of inaccuracy of measured 24-hour urine collections due to incomplete collection","volume":"21","author":"Mann","year":"2019","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"4S","key":"B10-20260430","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"7","key":"B11-20260430","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol."},{"issue":"10","key":"B12-20260430","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000526115","article-title":"Should the CKD EPI equation be used for estimation of the glomerular filtration rate in obese subjects?","volume":"47","author":"Domislovic","year":"2022","journal-title":"Kidney Blood Press Res."},{"issue":"1","key":"B13-20260430","first-page":"573","article-title":"Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma","volume":"104","author":"Utsu","year":"2025","journal-title":"Ann Hematol."},{"issue":"7","key":"B14-20260430","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/cam4.1075","article-title":"Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States","volume":"6","author":"Qian","year":"2017","journal-title":"Cancer Med."},{"issue":"9","key":"B15-20260430","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2022.12407","article-title":"Serum cystatin C for estimation of GFR","volume":"328","author":"Shlipak","year":"2022","journal-title":"JAMA."},{"issue":"1","key":"B16-20260430","doi-asserted-by":"crossref","first-page":"9151","DOI":"10.1038\/s41598-023-36390-z","article-title":"Adipose tissue is associated with kidney function parameters","volume":"13","author":"Mueller-Peltzer","year":"2023","journal-title":"Sci Rep."},{"issue":"1","key":"B17-20260430","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semerg.2018.07.005","article-title":"Influence of age, gender, smoking, diabetes, thyroid and cardiac dysfunctions on cystatin C biomarker","volume":"45","author":"Al Musaimi","year":"2019","journal-title":"Semergen."},{"issue":"4","key":"B18-20260430","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/ejh.12164","article-title":"The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?","volume":"91","author":"Terpos","year":"2013","journal-title":"Eur J Haematol."},{"issue":"5","key":"B19-20260430","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/j.ajkd.2023.04.002","article-title":"Discordances between Creatinine- and cystatin C-based estimated GFR and adverse clinical outcomes in routine clinical practice","volume":"82","author":"Carrero","year":"2023","journal-title":"Am J Kidney Dis."},{"issue":"8","key":"B20-20260430","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/00365513.2023.2297364","article-title":"Cystatin C and eGFR(CKD-EPI-CysC): novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma","volume":"83","author":"Niu","year":"2023","journal-title":"Scand J Clin Lab Invest."},{"issue":"4","key":"B21-20260430","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract."},{"key":"B22-20260430","doi-asserted-by":"crossref","first-page":"101162","DOI":"10.1016\/j.blre.2023.101162","article-title":"Optimizing high dose melphalan","volume":"64","author":"Shah","year":"2024","journal-title":"Blood Rev."},{"issue":"7","key":"B23-20260430","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s00277-020-04378-8","article-title":"Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies","volume":"100","author":"Gordillo","year":"2021","journal-title":"Ann Hematol."},{"issue":"8","key":"B24-20260430","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"8","key":"B25-20260430","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","article-title":"Assessment of GFR in patients with cancer: a statement from the American Society of Onco-Nephrology","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7","key":"B26-20260430","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1681\/ASN.2013090921","article-title":"Patient-reported and actionable safety events in CKD","volume":"25","author":"Ginsberg","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B27-20260430","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"B28-20260430","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"New Engl J Med."},{"issue":"12","key":"B29-20260430","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1681\/ASN.0000000000000227","article-title":"CKD-EPI and EKFC GFR estimating equations: performance and other considerations for selecting equations for implementation in adults","volume":"34","author":"Inker","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B30-20260430","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1681\/ASN.2014060607","article-title":"Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals","volume":"26","author":"Fan","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"B31-20260430","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/ajhp\/zxad058","article-title":"Medication dosing in adult patients with reduced lean body mass and kidney injury: a focus on cystatin C","volume":"80","author":"Erstad","year":"2023","journal-title":"Am J Health Syst Pharm."},{"issue":"4","key":"B32-20260430","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bcpt.13156","article-title":"Kidney function estimates using cystatin C versus creatinine: impact on medication prescribing in acutely hospitalized elderly patients","volume":"124","author":"Iversen","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"1","key":"B33-20260430","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12935-021-02313-z","article-title":"Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg\/m(2) conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis","volume":"21","author":"Gao","year":"2021","journal-title":"Cancer Cell Int."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:58:54Z","timestamp":1786478334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":33,"URL":"https:\/\/doi.org\/10.34067\/kid.0000001107","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-06-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}